Support to Research and Development at the International AIDS Vaccine Initiative

Development Objective

The Project Development Objective is to support the International AIDS Vaccine Initiative (IAVI) in the optimization and testing of one HIV vaccine candidate.

Key Details

Project Details

Project ID
P161232
Status
Closed
Team Leader
Robert Oelrichs
Borrower 2
International AIDS Vaccine Initiative

Country
World
Disclosure Date
August 22, 2016
Approval Date
(as of board presentation)
February 10, 2017
Effective Date
February 27, 2017

Total Project Cost 1
US$ 2.00 million
Implementing Agency
International AIDS Vaccine Initiative
Region
Other
Fiscal Year 3
2017

Commitment Amount
US$ 1.80 million
Environmental Category
B
Environmental and Social Risk
Not Applicable
Closing Date
September 30, 2018

Last Stage Reached
BANK APPROVED
Last Update Date
August 11, 2022

Notes
1. Total project cost includes funding from World Bank and non-bank sources in US$ millions. Active and Closed projects show current commitments. Proposed (pipeline) and dropped projects show the forecast amount. The commitment amount for projects in the pipeline is indicative and may be modified during the project preparation.
2. Borrower refers to the Borrower of a Loan or Recipient of a Grant.
3. ”Fiscal Year” is the fiscal year in which the project was approved (or dropped if the status is dropped). The World Bank's fiscal year is from July 1 - June 30. For example, a fiscal year of 1996 corresponds to July 1, 1995 - June 30, 1996.

Sectors

Themes

FY17 - Human Development and Gender

FY17 - Disease Control100%
- FY17 - HIV/AIDS100%

Project Map

Interactive Map

Finances

Financing Plan (US$ Millions)

Financier	Commitments
Free-standing TFs for HDNVP	1.80

Total Project Financing (US$ Millions)

Product Line	IBRD/IDA
IBRD Commitment	N/A
IDA Commitment	N/A
IBRD + IDA Commitment	N/A

Lending Instrument
Grant Amount	1.80
Total Project Cost**	2.00

Summary Status of World Bank Financing (US$ Millions) as of July 31, 2025

No data available.

Detailed Financial Activity as of July 31, 2025

No data available.

Footnotes

Ratings

IMPLEMENTATION RATINGS

Name	Review	Date
Progress towards achievement of PDO	Satisfactory	2018-09-26
Overall	Low	2018-09-26
Overall Implementation Progress (IP)	Satisfactory	2018-09-26

COMPLETION RATINGS

INDICATOR	IMPLEMENTATION COMPLETION & RESULTS REPORT: 04-11-2019
Outcomes	Highly Satisfactory
Risk to Development Outcome
Bank Performance	Highly Satisfactory
Borrower Performance
Government Performance
Implementing Agency

INDEPENDENT EVALUATION RATINGS

No data available.

Results Framework

PROJECT DEVELOPMENT OBJECTIVE INDICATORS

INDICATOR		BASELINE	CURRENT	TARGET

Vector has been optimized Value No Yes Yes
Date July 4, 2016 June 30, 2017 June 30, 2017
Comment
Vector testing has been initiated Value No Yes Yes
Date July 4, 2016 June 30, 2017 June 30, 2017
Comment
VSVdG-Env.BG505.1 vaccine vector has been evaluated Value No No Yes
Date September 6, 2017 June 30, 2018 June 30, 2018
Comment
Additional viral vectors have been developed Value No No Yes
Date September 6, 2017 September 28, 2019 June 30, 2018
Comment

INTERMEDIATE RESULTS INDICATORS

INDICATOR		BASELINE	CURRENT	TARGET

Five genetically modified VSVdG-Env.BG505 vaccines have been isolated and characteristics have been analyzed Value No Yes Yes
Date February 10, 2017 June 30, 2017 June 30, 2017
Comment

VSVdG-Env.BG505 mutants have been isolated after serial passage under conditions that select for viruses with increased replicativefitness. Mutant virus characteristics have been analyzed.	Value	No	Yes	Yes
	Date	February 10, 2017	June 30, 2017	June 30, 2017
	Comment

Candidate vaccines have been produced for a preclinical study. Value No Yes Yes
Date February 10, 2017 June 30, 2017 June 30, 2017
Comment
A decision to test new VSVdG-Env.BG505 vaccines or revise a macaque study to evaluate the requirement for three doses have been made. Value No Yes Yes
Date February 10, 2017 June 30, 2017 June 30, 2017
Comment
Preclinical study in non-human primates has been commenced. Value No Yes Yes
Date February 10, 2017 June 30, 2017 June 30, 2017
Comment
Determination of construction feasibility and replicative capacity of VSVdG-Env.BG505 with Env in position 2, 3 or 5 Value No No Yes
Date June 20, 2017 April 2, 2018 June 30, 2018
Comment
VSVdG-Env.BG505 position 1 vector with Matrix protein (M) modifications that will dampen the innate immune response rescued Value No No No
Date June 20, 2017 January 1, 2018 September 28, 2018
Comment
VSVdG-Env.BG505.1 vector with M modifications evaluated for genetic stability and replicative capacity Value No No No
Date June 20, 2017 September 28, 2018 September 28, 2018
Comment
Initiate VSVdG-Env.BG505 position 1 vector vaccine rescue in Early Development Laboratory Value No No No
Date June 20, 2017 September 28, 2018 September 28, 2018
Comment
Feasibility of VERO-CD4/CCR5 cell line also expressing VSV glycoprotein G is demonstrated Value No No Yes
Date June 20, 2017 December 29, 2017 June 30, 2018
Comment
Conduct serial passage of VSV New Jersey vector to improve replicative capacity and fitness of the virus Value No No Yes
Date June 20, 2017 December 29, 2017 June 30, 2018
Comment
Evaluate VSV New Jersey vector for improved fitness and utility as a vaccine platform Value No No Yes
Date June 20, 2017 September 28, 2018 June 30, 2018
Comment
Initiate VERO CD4/CCR5 VSV G expressing cell line in Early Development Laboratory Value No No No
Date September 6, 2017 September 28, 2018 September 28, 2018
Comment
Organize and facilitate meeting in conjunction with UHC Forum in December in Tokyo on Japanese investments in global health R&D Value No No Yes
Date September 6, 2017 January 1, 2018 June 30, 2018
Comment

Vector has been optimized	Value	No	Yes	Yes
	Date	July 4, 2016	June 30, 2017	June 30, 2017
	Comment

Vector testing has been initiated	Value	No	Yes	Yes
	Date	July 4, 2016	June 30, 2017	June 30, 2017
	Comment

Additional viral vectors have been developed	Value	No	No	Yes
	Date	September 6, 2017	September 28, 2019	June 30, 2018
	Comment

Determination of construction feasibility and replicative capacity of VSVdG-Env.BG505 with Env in position 2, 3 or 5	Value	No	No	Yes
	Date	June 20, 2017	April 2, 2018	June 30, 2018
	Comment

VSVdG-Env.BG505 position 1 vector with Matrix protein (M) modifications that will dampen the innate immune response rescued	Value	No	No	No
	Date	June 20, 2017	January 1, 2018	September 28, 2018
	Comment

VSVdG-Env.BG505.1 vector with M modifications evaluated for genetic stability and replicative capacity	Value	No	No	No
	Date	June 20, 2017	September 28, 2018	September 28, 2018
	Comment

Support to Research and Development at the International AIDS Vaccine Initiative

Development Objective

Key Details

Project Details

Sectors

Themes

Stay Connected, sign up for our:

Project Map

Finances

Financing Plan (US$ Millions)

Total Project Financing (US$ Millions)

Summary Status of World Bank Financing (US$ Millions) as of July 31, 2025

Detailed Financial Activity as of July 31, 2025

Ratings

IMPLEMENTATION RATINGS

COMPLETION RATINGS

INDEPENDENT EVALUATION RATINGS

Results Framework

PROJECT DEVELOPMENT OBJECTIVE INDICATORS

INTERMEDIATE RESULTS INDICATORS